Technical Analysis for DCTH - Delcath Systems, Inc.

Grade Last Price % Change Price Change
F 4.18 5.29% 0.21
DCTH closed up 5.29 percent on Monday, March 18, 2024, on 71 percent of normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
Earnings due: Mar 25
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
20 DMA Resistance Bearish 5.29%
50 DMA Resistance Bearish 5.29%
Shooting Star Candlestick Bearish 5.29%
Slingshot Bearish Bearish Swing Setup 5.29%
Stochastic Buy Signal Bullish 5.29%
Pocket Pivot Bullish Swing Setup 5.29%

   Recent Intraday Alerts

Alert Time
Down 1% about 11 hours ago
50 DMA Resistance about 13 hours ago
Rose Above Previous Day's High about 14 hours ago
Rose Above 50 DMA about 14 hours ago
Up 5% about 14 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's investigational products include melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its clinical development program consists of FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial that is in Phase 3 clinical trial for intrahepatic cholangiocarcinoma. It also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Classification

Sector: Healthcare
Industry: Medical Devices
Keywords: Medicine Clinical Development Oncology Chemotherapy Melanoma Chloride Specialty Drugs Carcinoma Hepatology Liver Cancer Cholangiocarcinoma Interventional Oncology Intrahepatic Cholangiocarcinoma Ocular Melanoma

Is DCTH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.99
52 Week Low 2.25
Average Volume 203,859
200-Day Moving Average 4.31
50-Day Moving Average 4.28
20-Day Moving Average 4.07
10-Day Moving Average 3.92
Average True Range 0.22
RSI (14) 52.61
ADX 17.92
+DI 25.07
-DI 17.16
Chandelier Exit (Long, 3 ATRs) 4.14
Chandelier Exit (Short, 3 ATRs) 4.37
Upper Bollinger Bands 4.41
Lower Bollinger Band 3.73
Percent B (%b) 0.66
BandWidth 16.79
MACD Line -0.11
MACD Signal Line -0.10
MACD Histogram -0.0026
Fundamentals Value
Market Cap 92.15 Million
Num Shares 22 Million
EPS -3.44
Price-to-Earnings (P/E) Ratio -1.22
Price-to-Sales 49.08
Price-to-Book 4.24
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.78
Resistance 3 (R3) 4.76 4.55 4.68
Resistance 2 (R2) 4.55 4.39 4.56 4.65
Resistance 1 (R1) 4.36 4.30 4.46 4.38 4.61
Pivot Point 4.15 4.15 4.19 4.16 4.15
Support 1 (S1) 3.96 3.99 4.06 3.98 3.75
Support 2 (S2) 3.75 3.90 3.76 3.71
Support 3 (S3) 3.56 3.75 3.68
Support 4 (S4) 3.58